These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36241154)

  • 1. Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring.
    Kocaturk E; Saini SS; Rubeiz CJ; Bernstein JA
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3099-3116. PubMed ID: 36241154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
    Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
    Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic improvement with colchicine in antihistamine- and omalizumab-resistant chronic spontaneous urticaria.
    Abe N; Bohgaki M; Kasahara H
    Clin Exp Dermatol; 2022 Dec; 47(12):2308-2310. PubMed ID: 36052842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
    Bei W; Qian J; Zilu Q; Kai C; Ruili J; Feng H; Liuqing C
    Int Immunopharmacol; 2023 Oct; 123():110577. PubMed ID: 37567010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
    He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
    Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
    Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
    JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Adjuvant Therapy in the Management of Chronic Urticaria.
    Keumala Budianti W; Mahri S; Almira D
    Actas Dermosifiliogr; 2023 Jun; 114(6):T523-T530. PubMed ID: 37172893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Adjuvant Therapy in the Management of Chronic Urticaria.
    Keumala Budianti W; Mahri S; Almira D
    Actas Dermosifiliogr; 2023 Jun; 114(6):523-530. PubMed ID: 36871821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children.
    Koosakulchai V; Yuenyongviwat A; Sangsupawanich P
    Asian Pac J Allergy Immunol; 2022 Jun; 40(2):121-125. PubMed ID: 32061244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
    Jain V; Giménez-Arnau A; Hayama K; Reich A; Carr W; Tillinghast J; Dahale S; Lheritier K; Walsh P; Zharkov A; Hugot S; Haemmerle S
    J Allergy Clin Immunol; 2024 Feb; 153(2):479-486.e4. PubMed ID: 37866460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
    Altrichter S; Staubach P; Pasha M; Singh B; Chang AT; Bernstein JA; Rasmussen HS; Siebenhaar F; Maurer M
    J Allergy Clin Immunol; 2022 May; 149(5):1683-1690.e7. PubMed ID: 34954198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
    Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
    Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging pharmacotherapy for chronic spontaneous Urticaria: a focus on non-biological therapeutics.
    Hon KL; Li JTS; Leung AKC; Lee VWY
    Expert Opin Pharmacother; 2021 Mar; 22(4):497-509. PubMed ID: 32990110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.
    Rubini NPM; Ensina LFC; Silva EMK; Sano F; Solé D
    Allergol Immunopathol (Madr); 2019; 47(6):515-522. PubMed ID: 31607407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
    Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
    Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.
    Ayse Ornek S; Orcen C; Church MK; Kocaturk E
    Int Immunopharmacol; 2022 Nov; 112():109198. PubMed ID: 36115277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of targeted therapy in chronic spontaneous urticaria.
    Min TK; Saini SS
    Ann Allergy Asthma Immunol; 2024 Oct; 133(4):367-373. PubMed ID: 38885835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.